Value & Access Experts Explain Price for Progress at EuroMeeting 2017
DIA: Driving Insights to Action

Value & Access Experts Explain Price for Progress at EuroMeeting 2017

2017-01-24
Through breakthrough therapy designations, adaptive designs and other innovations, the global regulatory environment is evolving to deliver therapeutic products to patients more quickly, although sometimes with less clinical data. Claes Buxfeldt, Global Price and Reimbursement Director at AstraZeneca in Sweden, and Ana Palma, Lead, Global HTA and Patient Access at Sobi in Belgium, explain how payer and health technology assessment processes are evolving to assess the value of these products, and preview...
View more
Comments (3)

More Episodes

All Episodes>>

Get this podcast on your phone, Free

Create Your Podcast In Minutes

  • Full-featured podcast site
  • Unlimited storage and bandwidth
  • Comprehensive podcast stats
  • Distribute to Apple Podcasts, Spotify, and more
  • Make money with your podcast
Get Started
It is Free